Patents by Inventor Tracy S. Mitchell

Tracy S. Mitchell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Serum albumin-binding fibronectin type III domains
    Patent number: 12534511
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: January 27, 2026
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
  • Compositions comprising PCSK9-binding molecules and methods of use
    Patent number: 12410236
    Abstract: The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).
    Type: Grant
    Filed: May 16, 2023
    Date of Patent: September 9, 2025
    Assignee: LIB Therapeutics, Inc.
    Inventors: Tracy S. Mitchell, Richard Mealey
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
    Publication number: 20240239870
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Application
    Filed: November 17, 2023
    Publication date: July 18, 2024
    Inventors: Ray CAMPHAUSEN, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • Fibronectin based scaffold domain proteins that bind PCSK9
    Patent number: 11858979
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: January 2, 2024
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • COMPOSITIONS COMPRISING PCSK9-BINDING MOLECULES AND METHODS OF USE
    Publication number: 20230295270
    Abstract: The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).
    Type: Application
    Filed: May 16, 2023
    Publication date: September 21, 2023
    Inventors: Tracy S. MITCHELL, Richard MEALEY
  • Compositions comprising PCSK9-binding molecules and methods of use
    Patent number: 11692021
    Abstract: The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: July 4, 2023
    Assignee: LIB Therapeutics, LLC
    Inventors: Tracy S. Mitchell, Richard Mealey
  • FAST-OFF RATE SERUM ALBUMIN BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20230145413
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: July 25, 2022
    Publication date: May 11, 2023
    Inventors: Stanley Richard KRYSTEK, Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Juhi JUNEJA
  • Fast-off rate serum albumin binding fibronectin type III domains
    Patent number: 11434275
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: September 6, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stanley Richard Krystek, Jr., Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Juhi Juneja
  • SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20220204589
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: November 16, 2021
    Publication date: June 30, 2022
    Inventors: Tracy S. MITCHELL, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
  • Serum albumin-binding fibronectin type III domains
    Patent number: 11203630
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: December 21, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
    Publication number: 20210277089
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Application
    Filed: February 16, 2021
    Publication date: September 9, 2021
    Inventors: Ray CAMPHAUSEN, Jonathan H. DAVIS, Sharon T. CLOAD, Fabienne M. DENHEZ, Amna SAEED-KOTHE, Dasa LIPOVSEK, Ching-Hsiung Frederick LO, Chee Meng LOW, Bowman MIAO, Tracy S. MITCHELL, Rex A. PARKER, Ginger C. RAKESTRAW, Katie A. RUSSO, Doree F. SITKOFF
  • Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS
    Publication number: 20210122805
    Abstract: The application provides Fc fusion proteins having novel arrangements. In one embodiment, the application provides Fc fusion proteins comprising a 10Fn3 domain. In another embodiment, the application provides Fc fusion proteins comprising linkers derived from the naturally occurring C-terminal tail regions of membrane bound or secretory immunoglobulins.
    Type: Application
    Filed: November 9, 2020
    Publication date: April 29, 2021
    Inventors: Ray CAMPHAUSEN, Amna SAEED-KOTHE, Jonathan DAVIS, Tracy S. MITCHELL
  • Fibronectin based scaffold domain proteins that bind PCSK9
    Patent number: 10947297
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: March 16, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • COMPOSITIONS COMPRISING PCSK9-BINDING MOLECULES AND METHODS OF USE
    Publication number: 20210002350
    Abstract: The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).
    Type: Application
    Filed: July 21, 2020
    Publication date: January 7, 2021
    Inventors: Tracy S. MITCHELL, Richard MEALEY
  • FAST-OFF RATE SERUM ALBUMIN BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20200283505
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: January 21, 2020
    Publication date: September 10, 2020
    Inventors: Stanley Richard KRYSTEK, JR., Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Juhi JUNEJA
  • Fast-off rate serum albumin binding fibronectin type III domains
    Patent number: 10766946
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 8, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stanley Richard Krystek, Jr., Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Juhi Juneja
  • Compositions comprising PCSK9-binding molecules and methods of use
    Patent number: 10738102
    Abstract: The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: August 11, 2020
    Assignee: LIB THERAPEUTICS, LLC.
    Inventors: Tracy S. Mitchell, Richard Mealey
  • COMPOSITIONS COMPRISING PCSK9-BINDING MOLECULES AND METHODS OF USE
    Publication number: 20200071386
    Abstract: The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).
    Type: Application
    Filed: September 20, 2019
    Publication date: March 5, 2020
    Inventors: Tracy S. MITCHELL, Richard MEALEY
  • SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20200048328
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: August 23, 2019
    Publication date: February 13, 2020
    Inventors: Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Rex PARKER, Ray CAMPHAUSEN, Jonathan DAVIS, David FABRIZIO
  • Serum albumin-binding fibronectin type III domains
    Patent number: 10442851
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: October 15, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan Davis, David Fabrizio